WebTailoring Adjuvant Endocrine Therapy for Premenopausal Women Absolute Improvements in Freedom from Distant Recurrence with Adjuvant Endocrine Therapies for Premenopausal … WebMar 7, 2024 · About 60% or 65% of patients in the SOFT and TEXT trials were node-positive. You can see in the red box down at the bottom of everybody getting OFS and looking at …

SOFT & TEXT Breast Cancer Trials

WebFeb 3, 2024 · We obtained data from all four identified trials (ABCSG XII, SOFT, TEXT, and HOBOE trials), which included 7030 women with ER-positive tumours enrolled between … WebObjective To analyze the applied condition of ovary function suppression (OFS) before and after joint analysis of TEXT and SOFT trials and SOFT trial, and to identify the relevant factors of OFS usage. Methods The analysis was performed in premenopausal women with hormone receptor (HR) positive breast cancer receiving surgical treatment from Apr 2013 … doi:10.1002/jame.20026

Frontiers Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate …

WebDec 1, 2013 · Introduction. In 2003 the International Breast Cancer Study Group (IBCSG) initiated a suite of three complementary tailored treatment investigations, the SOFT, TEXT … WebSOFT randomized, three-arm, phase III trial was designed to investigate the role of OFS and the role of the AI exemestane ( Figure 1), with three primary comparisons: tamoxifen+OFS … WebJul 1, 2016 · Purpose: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breast cancer, testing … doi 10.1002/smj.714